\u23f1 2 min read<\/p>\n
Alcon, an eye-care implants and consumables group based in Geneva and Texas, has published its quarterly results. The company operates in two main areas: eye surgery (Surgical) and vision care (Vision Care). In recent months, its intraocular implants have faced competitive pressure. The group has also abandoned the implant programmes acquired from PowerVision.<\/p>\n
In the third quarter of 2026, Alcon's revenue rose by 4.9% to 2.72 billion dollars<\/strong>, or 2.24 billion francs, according to the AWP news agency. Operating profit (EBIT) rose by 14.8% to 381 million dollars. Net profit reached 260 million dollars.<\/p>\n The Surgical division posted quarterly sales of 1.48 billion dollars (+4%), despite a 2% decline in implants, to 422 million. The Vision Care division reached 1.24 billion (+6%), driven by contact lenses (+4%) and ocular health (+8%).<\/p>\n Over nine months, sales grew by 7% to 8.18 billion dollars. Alcon has narrowed its annual targets: it now expects sales growth of around 6%, compared with 5 to 7% previously.<\/p>\nKey figures<\/h3>\n
\n
Who says what<\/h3>\n
\n
Analysis<\/h3>\n
\n
Further reading<\/h3>\n